Professor John Eisman AO
Senior Principal Research Fellow; Director, Bone and Mineral Research Program, Garvan Institute of Medical Research; Professor of Medicine, The University of New South Wales; Staff Endocrinologist, St Vincent's Hospital, Sydney
Email: j.eisman 'at' garvan.org.au
Research Group: Fracture Prevention Clinical Studies, Bone Genetics and Epidemiology
Education
1975 Fellow Royal Australian College of Physicians
1975 PhD University of Melbourne
1971 Member Royal Australian College of Physicians
1967 MBBS First Class Honours, Sydney University
1964 BSc (Medical) First Class Honours, Sydney University
Awards and Honours
1997 Order of Australia
1995 Sir Eric Sussman Award, Royal Australasian College of Physicians
Areas of Interest
Epidemiology and costs of osteoporosis, genetics of osteoporosis, molecular and cell biology of bone, vitamin D receptor, clinical research, bone strength, fracture riskNews
Why women should eat less, move more and consider wearing transdermal patches during menopause
MEDIA RELEASE:
24 Nov 2008
Weight and appetite experts from around the world met at a conference in Bangkok earlier this year to discuss sex differences in obesity. One line of discussion looked at factors leading to women’s weight gain during menopause, and how it might be avoided.
Glimpse the future of medical research at Garvan Open Day
MEDIA RELEASE:
18 Jul 2008
Garvan will open its doors on Sunday 17th August from 10am to 1pm for Open Day, giving the public the opportunity to meet and talk with leading scientists and learn about the future of science and medicine from some of the sharpest minds in Australia.
Study shows that prostate cancer increases the risk of bone fracture
MEDIA RELEASE:
14 May 2008
As unlikely as it sounds, scientists at Garvan have shown that there is a link between prostate cancer and a higher risk of bone fracture. Their study suggests that men with prostate cancer face a 50% higher risk of fracture, which increases to nearly 100% if they are receiving androgen deprivation therapy for their prostate cancer.
